#1 Clinical Trials Search in Europe

Clazakizumab

Clazakizumab is an investigational drug that has shown promise in treating various medical conditions. This article explores the use of Clazakizumab in clinical trials for different diseases, including kidney transplant rejection, rheumatoid arthritis, COVID-19, and inflammation in older adults. We’ll examine the drug’s mechanism of action, potential benefits, and ongoing research efforts to determine its safety and efficacy.

Table of Contents

What is Clazakizumab?

Clazakizumab is an investigational drug that belongs to a class of medications called monoclonal antibodies. It is specifically designed to target and block a protein in the body called interleukin-6 (IL-6). Clazakizumab is also known by other names such as Anti-IL-6 monoclonal antibody, BMS-945429, and ALD518[1][2].

How Does Clazakizumab Work?

Clazakizumab works by binding to and blocking the action of interleukin-6 (IL-6), which is a protein involved in inflammation in the body. By reducing the activity of IL-6, clazakizumab aims to decrease inflammation and potentially improve various conditions where excessive inflammation plays a role[1].

Conditions Treated with Clazakizumab

Clazakizumab is being studied for its potential to treat several conditions, including:

  • Kidney Transplant Complications: Clazakizumab is being investigated for treating antibody-mediated rejection (ABMR) in kidney transplant patients. ABMR is a serious complication that can lead to transplant failure[3][4].
  • COVID-19: Some studies are exploring the use of clazakizumab in patients with severe COVID-19 infection, particularly those experiencing a “cytokine storm” – an excessive immune response that can cause severe lung damage[5][6].
  • Rheumatoid Arthritis: Clazakizumab has been studied in patients with moderate to severe rheumatoid arthritis who haven’t responded well to other treatments[2].
  • Asthma: Research is ongoing to evaluate clazakizumab’s potential in treating severe asthma[1].
  • Inflammation in Older Adults: A study is investigating whether clazakizumab can improve physical function in older adults by reducing inflammation[7].

Administration and Dosage

Clazakizumab is typically administered as a subcutaneous injection (an injection under the skin) or intravenously (directly into a vein). The dosage and frequency of administration can vary depending on the condition being treated and the specific clinical trial. Some common dosages being studied include:

  • 25 mg given every 4 weeks for kidney transplant complications[3]
  • 12.5 mg or 25 mg given intravenously for severe COVID-19[6]
  • Various doses ranging from 12.5 mg to 25 mg for rheumatoid arthritis[2]
  • 5 mg given monthly for older adults with inflammation[7]

Ongoing Research and Clinical Trials

Clazakizumab is still considered an investigational drug, which means it’s not yet approved for general use by regulatory agencies like the FDA. Several clinical trials are currently underway to evaluate its safety and effectiveness for various conditions. These trials aim to determine the optimal dosage, assess potential side effects, and measure how well the drug works compared to existing treatments or placebos (inactive substances)[3][4][5][6][2][1][7].

Potential Side Effects

As with any medication, clazakizumab may cause side effects. The full range of potential side effects is still being studied in clinical trials. Some of the effects being monitored include:

  • Infections: Since clazakizumab affects the immune system, there may be an increased risk of infections[3].
  • Changes in blood cell counts: The drug may affect white blood cell, neutrophil, or platelet counts[7].
  • Liver function changes: Researchers are monitoring for potential effects on liver enzymes[7].
  • Changes in cholesterol levels[7].
  • Infusion-related reactions: For intravenous administration, there may be reactions during or shortly after the infusion[6].

It’s important to note that the safety profile of clazakizumab is still being established through ongoing clinical trials. Patients participating in these trials are closely monitored for any adverse effects.

Condition Trial Phase Key Findings/Objectives
Kidney Transplant Rejection Phase I/II Investigating safety and efficacy in reducing donor-specific antibodies and improving transplant outcomes
Rheumatoid Arthritis Phase IIb Evaluating different doses for efficacy in reducing disease activity and improving physical function
COVID-19 Phase II/III Assessing safety and efficacy in reducing inflammation and improving outcomes in severe cases
Inflammation in Older Adults Phase I/II Studying effects on mobility, physical function, and inflammation biomarkers in older adults

FAQ

  • What is Clazakizumab? Clazakizumab is a genetically engineered humanized monoclonal antibody that binds to and blocks the action of interleukin-6 (IL-6), a protein involved in inflammation. It is being studied as a potential treatment for various conditions characterized by excessive inflammation.
  • What medical conditions is Clazakizumab being tested for? Clazakizumab is being investigated in clinical trials for several conditions, including kidney transplant rejection, rheumatoid arthritis, COVID-19, and inflammation-related mobility issues in older adults.
  • How is Clazakizumab administered? Clazakizumab is typically administered as a subcutaneous injection or intravenous infusion. The dosage and frequency of administration vary depending on the specific clinical trial and condition being treated.
  • What are the potential side effects of Clazakizumab? As with any investigational drug, the full range of side effects is still being studied. Clinical trials are monitoring for adverse events, which may include infections, changes in blood cell counts, and liver function abnormalities. The safety profile is being carefully evaluated in each trial.
  • When might Clazakizumab become available for general use? The availability of Clazakizumab for general use depends on the results of ongoing clinical trials and regulatory approval processes. It is still in the investigational stage, and more research is needed to determine its safety and efficacy for various conditions.

Ongoing Clinical Trials on Clazakizumab

  • Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

    Recruiting

    4 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

Glossary

  • Antibody-mediated Rejection (ABMR): A type of transplant rejection where the recipient's immune system produces antibodies that attack the transplanted organ.
  • Interleukin-6 (IL-6): A protein involved in the body's immune response and inflammation processes.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used to treat various diseases.
  • Cytokine Storm: A severe immune reaction in which the body releases too many cytokines into the blood too quickly, potentially leading to organ failure.
  • Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
  • Acute Respiratory Distress Syndrome (ARDS): A serious lung condition that causes low blood oxygen levels, often occurring in severely ill patients.
  • C-reactive Protein (CRP): A protein made by the liver that increases when there is inflammation in the body.
  • Extracorporeal Membrane Oxygenation (ECMO): A life support machine that takes over the function of the heart and lungs in severely ill patients.
  • Disease Activity Score (DAS28): A measure of disease activity in rheumatoid arthritis, which includes assessment of 28 joints.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the active drug being tested.

References

  1. https://clinicaltrials.gov/study/NCT04129931
  2. https://clinicaltrials.gov/study/NCT02015520
  3. https://clinicaltrials.gov/study/NCT03444103
  4. https://clinicaltrials.gov/study/NCT03380962
  5. https://clinicaltrials.gov/study/NCT04348500
  6. https://clinicaltrials.gov/study/NCT04343989
  7. https://clinicaltrials.gov/study/NCT05727384